Introduction
A spergillus is ubiquitous, occurring in mycelial form, which is thermo tolerant and grows at 15°C-53°C, the optimum being 37°C-40°C and humid conditions. It is present in the environment, decaying vegetation, fallen leaves, mulch, water, saunas, basements, crawl spaces, bedding, and some foodstuffs and even in marijuana.
Pulmonary aspergillosis is a clinical spectrum of lung disease caused by the fungus Aspergillus. The classification of pulmonary aspergillosis includes saprophytic aspergillosis in the form of pulmonary aspergilloma, immune disease in the form of allergic bronchopulmonary aspergillosis (ABPA), IgE mediated asthma, hypersensitivity pneumonitis, allergic Aspergillus sinusitis (AAS) and infectious disease in the form of invasive and semi-invasive pulmonary aspergillosis. [1] One of the latest study also categorised aspergillosis related respiratory disorders into upper and lower respiratory tract disorders. [2] ABPA is the commonest disease among allergic bronchopulmonary mycoses. ABPA is a hypersensitivity immunological lung disorder caused by species of the dimorphic fungus Aspergillus, commonly Aspergillus fumigatus (about 95%) and rarely by Aspergillus flavus, Aspergillus niger, Aspergillus oryzae, Aspergillus sydowi, Aspergillus terreus, Aspergillus glaucus, Aspergillus nidulans, and Aspergillus clavatus'. Other fungi such as Candida, Helminthosporium, Curvularia, Drechslera, Pseudallescheria boydii, and Fusarium vasinfectum have also been found to cause an identical syndrome. [3] Clinically manifesting as chronic asthma, recurrent pulmonary infiltrates, and bronchiectasis. [4] [5] [6] [7] [8] [9] [10] [11] [12] The condition has immunologic features of immediate hypersensitivity (Type I), antigen-antibody complexes (Type III), and eosinophil-rich inflammatory cell responses (Type IVb), based on the revised Gell and Coombs classification of immunologic hypersensitivity. [13, 14] The First case of ABPA was reported in England [15] in 1952 and in India [16] in 1971. Since then, a number of cases have been reported from all over the world. Concomitant occurrence of ABPA and AAS is now being increasingly recognised which is also called as "sinobronchial allergic mycosis" syndrome. [17] ABPA is commonly associated in patients with chronic bronchial asthma and cystic fibrosis but can also occur in non-asthmatics. [18] A new phenotype of asthma has been described recently, namely severe asthma with fungal sensitization (SAFS). SAFS can be conceptualized as a continuum of fungal sensitization, with asthma at one end and ABPA at the other. It is diagnosed by the presence of SAFS, and exclusion of ABPA. [19] 
Prevalence of Allergic Bronchopulmonary Aspergillosis
ABPA has long been reported to be common in U. K. where it is the cause of 50%-80% of cases of the pulmonary eosinophilia. [10] The exact prevalence of ABPA is not known but contemporary estimates suggested that ABPA complicates 1%-11% of all chronic cases of bronchial asthma. [20] [21] [22] [23] [24] [25] [26] [27] [28] Many case series of ABPA were reported from India. [29] [30] [31] [32] A very recent study from India, however, found a higher prevalence of Aspergillus sensitization (39.5%) and ABPA (27%) in 564 patients with asthma. [33] Alok Nath et al. in their latest study on 350 patients found the prevalence of Aspergillus hypersensitivity (AH) and ABPA to be 35.1% and 21.7%, respectively. [34] The condition is being increasingly recognized and the estimated prevalence rates in recent publications have been reported ranging from 5.9% to 20.5% for ABPA and 38%-43% for AH. [35, 36] Prevalence data from this part of the country are sparse.
Immunopathology of Allergic Bronchopulmonary Aspergillosis
ABPA patients are atopic with history of chronic asthma. The basic underlying immuno-pathophysiologic process in ABPA is a hypersensitivity reaction to fungus in the bronchial tree. In susceptible individuals after inhalation of fungal spores in the bronchi, fungi germinate and form vegetative elements (hyphae). Local immunologic reactions and stagnation of tenacious sputum in bronchial airways favor the trapping of fungal spores and further colonization. Antigenic substance of the fungus stimulates formation of IgE, IgG, and IgA antibodies. ABPA is immunologically classified as it gives both Type I (immediate) and Type III (Arthus, antigen-antibody immune complex) hypersensitivity reactions. Type I reaction is IgE mediated and responsible for accumulation of eosinophils, bronchospasm, edema leading to acute symptoms of diseases. Type III reaction results in polymorph aggregation, inflammation of bronchial and peribronchial tissues and is responsible for the radiological features of ABPA. Recently, possible role of Type IVb [13, 14] hypersensitivity reaction has also been observed in patients with ABPA and the presence of parenchymal granuloma and mononuclear cell infiltration seen on histopathology. Long-standing involvement of the bronchial tree leads to bronchiectasis, fibrosis, lung contraction, and lobar shrinkage. [10] 
Clinical Presentation
Patients are usually atopic with previous history of bronchial asthma. The onset is insidious with constitutional symptoms like anorexia, fatigue, weight loss, headache, generalized aches and pains, and low-grade fever. The frequency and severity of symptoms of underlying asthma are not fully controlled with usual anti-asthmatic therapy. It is characterized by repeated episodes of exacerbation with periods of remission, if untreated may progress to fibrotic lung disease. It may occur at any age but usually in the age group of 20-40 years. Patients with chronic fibrotic disease may present with cyanosis, corpulmonale, and respiratory failure. However, symptoms have little or no relationship to severity or chronicity of the disease, as one-third patients may be relatively asymptomatic in spite of extensive radiological shadows. [37] Golden-brown rubbery flecks or plugs of sputum production is characteristic and has been reported in 5%-54% of cases. [26] These plugs consist of fungal hyphae with eosinophils and mucous. Cough, breathlessness and wheezing are the common symptoms seen in ABPA. Hemoptysis has been reported in 34%-85% of cases, while pleuritic chest pain may be present in 50% of cases. In one of his study author found that hemoptysis is found in 28.6% of patients. [38] Chronic cases of ABPA may rarely present with symptoms of bronchiectasis. On clinical examination of chest, wheezing and diffuse crepitations are the common findings but tachypnea, cyanosis, features of cor pulmonale and sometimes hypertrophic osteoarthropathy may be seen. The disease is often incorrectly diagnosed as tuberculosis, bronchiectasis and bacterial pneumonia. [10] Almost half of the ABPA patients are initially misdiagnosed as pulmonary tuberculosis. [28] Diagnostic Approach ABPA is suspected in any patient with asthma with lung shadows on chest skiagram and peripheral blood eosinophilia. All the features are not necessary to diagnose ABPA. The important diagnostic criteria are the presence of recurrent pulmonary infiltrates, peripheral blood eosinophilia and positive skin test to Aspergillus antigen. Criteria for diagnosis of SAFS include History of poorly controlled asthma (>500 μg/day of fluticasone or the equivalent, near continuous oral corticosteroids for >6 months, or >2 oral steroid tapers per year. Total serum IgE <1000 IU/ml, Positive immediate skin test reactivity to A. fumigatus, elevated specific serum IgE to A. fumigatus or absence of serum precipitins (by gel diffusion) and elevated specific serum IgG to A. fumigatus and No radiographic evidence of bronchiectasis or infiltrates. [19] 
Radiological Features Chest X-ray
Radiological features in patients of ABPA may be transient (acute) or permanent (chronic). Transient shadows may clear with or without steroid therapy and are mainly due to pulmonary infiltrates and stagnation of secretions in damaged bronchi. [39, 40] Transient shadows are perihilar infiltrates mimicking adenopathy, air fluid levels from dilated central bronchi filled with fluid and debris. Parenchymal abnormalities are more common and present in 80%-90% patients of ABPA as ill-defined homogenous shadows without evidence of loss of volume which may be of 5-15 mm in size or more as massive/lobar in extent, may be unilateral or bilateral, more in upper lobes, resolve (fleeting/migratory shadows) often after expectoration of bronchial plugs but tends to recur in same/other places. Sometimes pulmonary shadows mimic carcinoma.
Fleeting shadows are characteristic of ABPA, author in one of his study found 66.7% patients had fleeting shadows. Author described "walking pneumonia" as a clue to diagnosis of ABPA. [41] Bronchial abnormalities occur in 50%-70% of episodes of acute ABPA consists of tramline, parallel lines and ring shadows which represents normal or abnormal bronchial wall. The impacted bronchus may appear as full wine glass having an open upper end with tapering lower end, [42] gloved finger 2-3 centimeter long and 5-8 mm wide, and inverted V, Y or toothpaste shadows. Gloved-finger shadows are due to distally occluded bronchi filled with secretions. Tram lime shadows are the thickened walls of undilated bronchi, so the distance between lines is that of a normal bronchus while parallel lines shadows represent walls of bronchiectatic bronchi, the distance between walls is greater than normal. Permanent (chronic) changes reflect histological abnormalities secondary to repeated acute episodes of ABPA, and are often associated with physiologic abnormalities. Rarely cavitations, local emphysema, pulmonary fibrosis or contracted upper lobe, honeycombing, collapse due to mucous impaction, and spontaneous pneumothorax [43] are recognized, even total collapse of lung has been reported. [44] 
Computed tomography
Conventional tomography has been shown to be more sensitive than the plain chest radiograph. Computerized tomography might be useful in the assessment of extent of disease. High resolution computed tomography (HRCT) is a sensitive noninvasive technique for the recognition of ABPA. Proximal bronchiectasis is due to deposition of immune complex in proximal airways. Bronchiectasis, centrilobular nodules and mucoid impaction are main features of ABPA. [45] proximal bronchiectasis with ABPA may be seen in 40% patients [46] and characterized by string of pearls and signet ring appearance as described by Webb, et al. [47] proximal bronchiectasis (in 2 nd , 3 rd , 4 th order large bronchi) is an important diagnostic feature of ABPA with normal small bronchi and bronchioles. [48] 
R a d i o l o g i c a l c l a s s i f i c a t i o n o f a l l e r g i c bronchopulmonary aspergillosis
Serological ABPA (ABPA-S) (mild), ABPA-central b r o n c h i e c t a s i s ( A B P A -C B ) ( m o d e r a t e ) , a n d ABPA-CB-other radiologic findings (ORF). [49] In ABPA-S all the diagnostic features of ABPA are present except evidence of proximal bronchiectasis on HRCT. It is believed that patients with ABPA-S have milder clinical course and less severe immunological findings when compared to ABPA-CB. In ABPA-CB all findings of ABPA including proximal bronchiectasis on HRCT present however in ABPA-CB-ORF all findings of ABPA and CB along with other radiological features such as pulmonary fibrosis, bleb, bullae, pneumothorax, parenchymal scarring, emphysematous change, multiple cyst, fibrocavitory lesions, Aspergilloma, ground glass appearance, collapse, mediastinal lymph node, pleural effusion and pleural thickening. Newly proposed radiological classification of ABPA based on computed tomography chest findings, categorizes ABPA as ABPA-S, ABPA with bronchiectasis, ABPA with high attenuation mucus and ABPA with chronic pleuropulmonary fibrosis. [50] Laboratory Investigations 1 . Peripheral blood eosinophilia (usually 1000-3000/m 3 ), leucocytosis and raised ESR in acute episodes and sputum contain eosinophils in most of the cases 2. Serological tests: Increase in total IgE and specific IgE and IgG precipitating antibodies (in 70%) against A. fumigatus. [51, 52] Both total and specific IgE levels are high during development of pulmonary infiltrates and decrease after remission. The total IgE levels are >1000 IU/ml may be as high as 20,000 IU/ml in acute cases except in cases that are in remission or on steroids therapy. [53] Precipitating antibodies against A. fumigatus are present in most of cases of ABPA with pulmonary infiltrates and diminished after steroid therapy [ 
Minor criteria
History of expectorating golden brown plugs in sputum, Positive sputum smear and culture for Aspergillus species, Late Type III (Arthus) skin reactivity to A. fumigatus.
The presence of six of eight major criteria makes the diagnosis almost certain.
Latest criteria do not differentiates in major and minor, eight diagnostic criteria are laid down to detect ABPA suggested by Patterson et al. 1997 [7] as follows:
Asthma (mild or severe) or cystic fibrosis, Immediate cutaneous reactivity to Aspergillus antigen, Current or previous pulmonary infiltrates, Elevated total IgE concentration (>l mg/L), Precipitin antibodies to A. fumigatus, Peripheral blood eosinophilia, Elevated serum IgE and/or IgG-against A. fumigatus and Proximal bronchiectasis.
Staging of Allergic Bronchopulmonary Aspergillosis
Five stages of allergic bronchopulmonary aspergillosis has been described according to Patterson et al. [7] 1. Acute stage: Symptomatic presenting with fever, sputum production and symptoms of asthma. [50] has been proposed:
• Stage 0 Asymptomatic: Patient fulfills GINA definition of controlled asthma, patient fulfills the diagnostic criteria of ABPA, and has not been previously diagnosed to have ABPA • Stage 1 Acute: Patient has uncontrolled asthma, fulfils the diagnostic criteria for ABPA and not previously diagnosed to have ABPA 
Treatment of Allergic Bronchopulmonary Aspergillosis
Oral corticosteroid remains the cornerstone for the treatment of ABPA. [55] The goal of therapy is to achieve symptom resolution, clearance of radiographic infiltrates, and establishment of a stable baseline serum level of total IgE. There are two dose schedules of oral glucocorticoid therapy, low dose and high dose. In low dose oral glucocorticoid therapy, Prednisolone 0.5 mg/kg/d is given for 2 wk, then on alternate day for 6-8 weeks and then tapered 5-10 mg every 2 weeks and then discontinued. In high dose glucocoticoid therapy Prednisolone 0.75 mg/kg is given for 6 weeks, followed by 0.5 mg/kg for 6 weeks, then taper 5 mg every 6 weeks to continue for a total of atleast 6-12 months. Higher dose and prolonged use of steroids associated with better outcome. [56] During the acute episode, usual starting dose of prednisone is 0.5 mg/kg daily for 2 weeks then reduced to an alternate day regime for 2-3 months, after that it should be tapered off in next 2-3 months. Repeat chest X-ray in 1 month should demonstrate clearing of the infiltrates. The total serum IgE level also regresses along with the infiltrates. The failure of the total serum IgE level to decrease suggests continuation of active disease and requires additional corticosteroids.
Following successful infiltrate clearing there is a reduction in total serum IgE and remission of the patient's symptoms. The total serum IgE level, chest x ray, absolute eosinophil count should then be followed at 6-8 weeks intervals regularly. The goal of glucocorticoid therapy is not normalization of total S. IgE but reduction in total S. IgE by 35%-50% from baseline that defines remission by 6 weeks Serial total serum IgE levels are important for follow-up care. [57] A sudden doubling of total serum IgE levels over baseline usually heralds activity of disease. Such activity can be aborted or even prevented with increased dose of prednisone at the time when the elevated level of IgE is noted.
Patients who have remission of ABPA may discontinue prednisone. The remission may last for years or may be permanent. In patients with recurrent flares of ABPA or in those with severe persistent asthma, long-term corticosteroid therapy may be necessary to control their symptoms. Patients in the fibrotic stage of ABPA may have increased sputum volume as a result of infection.
Measures such as postural drainage and antibiotics may be useful, but with deterioration, exercise tolerance decreases and oxygen therapy may be needed.
Optimization of baseline asthma therapy is essential with inhaled corticosteroid and β 2 -agonists. In addition, prophylactic measures should be instituted when indicated to prevent the adverse effects of long-term corticosteroid treatment such as osteoporosis. Thus, patients who will be taking prednisolone for more than 2-3 months should be considered for bone mineral density analysis to direct commencement of calcium/Vitamin D supplementation with or without bisphosphonates. [58] 
Role of Antifungal Drugs
Pooled analysis showed that itraconazole could significantly decrease IgE levels by >25% when compared to placebo, reduction in steroid dose by ≥50%; increase in exercise tolerance by ≥25%, improvement of ≥25% in results of spirometry, resolution of pulmonary opacities but failed to reach statistical but did not cause significant improvement in lung function but did not cause significant improvement in lung function. [50, 58] Itraconazole modified the immunologic activation associated with ABPA and improve clinical outcome at least over the period of 16 wks. A decline in exacerbation rates was also seen. At present, itraconazole should be limited in cases where oral steroids are contraindicated or refused by patients. In patients requiring high doses of oral steroid, itraconazole may allow reduction in steroid doses, but should not replace the need of steroid; the major concern being no long term trials and adrenal supression with itraconazole. Thus long term trials are required before firm recommendation can be made for the use of itraconazole in ABPA. The use of omalizumab in ABPA has been associated with improvement in symptoms, reduction in exacerbations and asthma hospitalizations, improvement in lung function and reduction in dose of oral steroids. [50] Recently voriconazole has also been tried in the treatment of ABPA. [59] [60] [61] 
Conclusion
Presently ABPA is one of the important emerging immunologically mediated respiratory diseases, commonly presenting in patients of asthma. It should be highly suspected in patients presenting with history of asthma, peripheral blood eosinophilia, recurrent pneumonitits or transient (fleeting) pulmonary infiltrates mimicking pulmonary tuberculosis. In such suspected patients, detailed evaluations are needed to prove the diagnosis. Early diagnosis and proper treatment may alter the prognosis of disease and further prevent end stage lung fibrosis.
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